GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis

Back

ESC Professional Premium Access

GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis

Session: Diabetes, obesity, and the heart

Topic: Antidiabetic Pharmacotherapy

Speaker: Ms K. Soerensen (Copenhagen, DK)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Ms Kathrine Kold Soerensen

North Zealand University Hospital, Copenhagen (Denmark)

1 follower

6 more presentations in this session

Dapagliflozin versus empagliflozin and major adverse cardiovascular events in type 2 diabetes: a nationwide cohort study

Speaker: Doctor A. Alhakak (Copenhagen, DK)

The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in epicardial adipose tissue modulation: a meta-analysis

Speaker: Doctor P. Theofilis (Athens, GR)

The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease

Speaker: Doctor J. Tjerkaski (Stockholm, SE)

Impact of SGLT2 inhibitor dapagliflozin on myocardial protein profile in rats with long-standing Type 1 diabetes mellitus

Speaker: Doctor E. Rodrigues (Botucatu, BR)

Body mass index and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS

Speaker: Doctor M. Pareek (Copenhagen, DK)

Access the full session

Diabetes, obesity, and the heart

Speakers: Ms K. Soerensen, Doctor A. Alhakak, Doctor P. Theofilis, Doctor J. Tjerkaski, Doctor E. Rodrigues...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources